NYKODE THERAPEUTICS AS
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 --
業務概覽 Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need. It operates in United States of America.
公司地址 Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
電話號碼 +47 22958193
傳真號碼 --
公司網頁 https://www.nykode.com
員工數量 59
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Michael Thyrring Engsig Chief Executive Officer -- 17/04/2026
Mr. Harald Gurvin Chief Financial Officer -- 17/04/2026
 
董事會成員
董事會 職務 更新日期
Dr. Susanne Stuffers, PhD Independent Director 17/04/2026
Dr. John Beadle Independent Director 17/04/2026
Dr. Barbara Krebs-Pohl Chairman of the Board 17/04/2026
Dr. Trygve Lauvdal, PhD Director 17/04/2026
Mr. Christian Abyholm Director 17/04/2026
 
所屬ETF (更新日期: 09/05/2026 03:15)
代號 名稱 佔比% ▼ 持有日期
DFISDimensional International Small Cap ETF0.02%30/04/2026
DFICDimensional International Core Eq 2 ETF0.01%30/04/2026
DFAXDimensional World ex US Core Eq 2 ETF0.01%30/04/2026
SPEUState Street® SPDR® Portfolio Europe ETF0.003%30/04/2026
ENORiShares MSCI Norway ETF<0.000001%06/03/2026
GWXState Street® SPDR® S&P® Intl Sm Cp ETF<0.000001%22/09/2025
HSCZiShares Currency Hdgd MSCI EAFE SmCp ETF<0.000001%03/03/2026
IEFAiShares Core MSCI EAFE ETF<0.000001%04/03/2026
IEURiShares Core MSCI Europe ETF<0.000001%06/03/2026
IEUSiShares MSCI Europe Small-Cap ETF<0.000001%06/03/2026
SCZiShares MSCI EAFE Small-Cap ETF<0.000001%06/03/2026
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.